New hope for advanced colon cancer: which drug combo works best?
NCT ID NCT03303495
First seen Jun 10, 2026 · Last updated Jun 14, 2026 · Updated 1 time
Summary
This study tests two different chemotherapy combinations for people with metastatic colorectal cancer that has spread and needs a second treatment. About 280 adults will be randomly assigned to receive either FOLFIRI or irinotecan, with or without bevacizumab. The goal is to see which approach helps patients live longer without the cancer growing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer center of Sun Yat-sen University
RECRUITINGGuangzhou, Guangdong, 510060, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.
Conditions inferred from the trial description
These were inferred from the trial's summary, not listed by the trial registrant.